Status:
RECRUITING
Pediatric -Adult Care Transition Program of Patients With Sickle Cell Disease
Lead Sponsor:
Hospices Civils de Lyon
Conditions:
Sickle Cell Disease
Eligibility:
All Genders
16-17 years
Phase:
NA
Brief Summary
Background The pediatric-adult care transition is a risk-disrupting time for patients with chronic disease. This care transition takes place during adolescence; a period of psychological upheavals and...
Eligibility Criteria
Inclusion
- For patients :
- Age: 16-17 years,
- With major sickle cell syndrome, defined by hemoglobinopathy of homozygosity SS, or double heterozygosity SC or Sβ-thalassemia,
- Benefiting from social insurance of the type "Affection of long duration" (ALD).
- For family members :
- Included children's parents or legal representatives,
- Accepting to participate in the study and having signed the informed consent.
Exclusion
- Presenting a cognitive or psychiatric disorder known and major that may hinder interventions or evaluation, the judgment of the investigator, and / or having a family history with this type of disorders,
- Cured of SCD by an allograft of hematopoietic stem cells.
Key Trial Info
Start Date :
January 16 2019
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
April 16 2027
Estimated Enrollment :
196 Patients enrolled
Trial Details
Trial ID
NCT03786549
Start Date
January 16 2019
End Date
April 16 2027
Last Update
June 21 2024
Active Locations (8)
Enter a location and click search to find clinical trials sorted by distance.
1
CHU de Fort de France
Fort-de-France-La Martinique, La Martinique, France
2
Centre Hospitalier Intercommunal de Creteil
Créteil, France
3
Hôpital Mondor
Créteil, France
4
Hôpital Bicêtre
Le Kremlin-Bicêtre, France